Key Highlights

  • SELLAS Life Sciences (NASDAQ:SLS) was trading down 13.98% on Thursday, November 19, 2026, a day after launching a proposed USD 150.0 million underwritten offering with underwriters able to add up to USD 22.5 million within 30 days.
  • ClearOne (NASDAQ:CLRO) was trading down 11.59% after completing a USD 4.00 per share sale of 999,999 shares on November 17, 2026, lifting shares outstanding to 3,675,411.
  • PepGen (NASDAQ:PEPG) was trading up 8.82% even though its 25 million share offering priced at USD 5.00 on November 11, 2026, a deal expected to bring in USD 125 million before fees.
  • newcleo (NASDAQ:NWCL) was trading down 6.9% after a November 18, 2026 prospectus supplement covering up to 217,834,936 ordinary shares, about 77% of shares outstanding (calculated).

SELLAS Life Sciences (NASDAQ:SLS): A USD 150 Million Raise After the Rally

SELLAS Life Sciences (NASDAQ:SLS) fell 13.98% in midday market data on Thursday, November 19, 2026, which implies a prior close near USD 17.95 (calculated). Two days earlier, on November 17, 2026, the REGAL Phase 3 study of galinpepimut-S in acute myeloid leukemia reported success on overall survival: 24.0 months of median survival versus 14.7 months on best available therapy. Later that day it launched a proposed public offering of USD 150.0 million, with J.P. Morgan and TD Cowen as joint book-running managers and an extra allotment worth up to USD 22.5 million that underwriters may take within 30 days. Every share is sold by the company, so ownership is spread across a larger base. No price per share or use of proceeds was stated, and no final pricing was confirmed. Its cash balance stood at USD 134.7 million as of the end of September 2026, and it reported a third-quarter net loss of USD 10.1 million. It plans to meet the FDA on an accelerated filing path and to prepare a Biologics License Application for the first half of 2027. The main risks are that the study was open-label with 126 patients, that the p-value of 0.035 sits only modestly below 0.05, and that the offering terms are not assured. No other company announcement was found, so dilution is the likeliest driver, not a confirmed one.

ClearOne (NASDAQ:CLRO): A USD 4.00 Placement and a Nasdaq Hearing

ClearOne (NASDAQ:CLRO) was trading down 11.59% on November 19, 2026, after a prior close near USD 6.90 (calculated), a level well above the USD 4.00 issue price. ClearOne completed the issuance of 999,999 shares at USD 4.00 on November 17, 2026, for total consideration of USD 3,999,998. Cash received before costs was about USD 2.756 million, and the largest holder, First Finance, swapped USD 1,244,458 of what it was owed, interest included, for 311,114 shares. The share count climbed to 3,675,411, so the newly issued stock is about 27% of the total (calculated). The financing is tied to a listing dispute: Nasdaq staff determined on October 8, 2026 that the company had missed the USD 2.5 million minimum Equity requirement, and a hearing was scheduled for November 17, 2026. The company submitted preliminary, unaudited pro forma equity of USD 3.282 million, which audit adjustments and losses could reduce, and Nasdaq has not confirmed the deficiency is resolved. Published coverage also reported zero continuing Revenue and a pending Merger with Cortigent and Vivani Medical, both unconfirmed here. No separate company announcement for the move was found, and with so few shares a small number of trades can move the price.

PepGen (NASDAQ:PEPG): Rising While Still Below Its Offering Price

PepGen (NASDAQ:PEPG) traded 8.82% higher at USD 4.16 on November 19, 2026, still roughly 16.8% under the USD 5.00 deal price (simple arithmetic on two published numbers). That makes it the one gainer in this group. On November 11, 2026 PepGen sold 25 million shares in an underwritten deal at USD 5.00, which should bring in USD 125 million before fees, and underwriters hold a 30-day option on up to 3.75 million more. It followed Phase 2 data for PGN-EDODM1 in myotonic dystrophy type 1, where the 10 mg/kg dose produced average splicing correction of 46.5%. Cash was USD 104.8 million at September 30, 2026, and adding the gross proceeds gives roughly USD 229.8 million before fees and later spending (calculated). The third-quarter net loss was USD 19.4 million. The key risk is an FDA partial clinical hold imposed in March 2026, which a planned regulatory meeting depends on lifting. Searches found no company news for November 17 to 19, so this gain cannot be linked to a new event, and the closing of the offering was not confirmed.

newcleo (NASDAQ:NWCL): A Resale Prospectus Alongside Rising Cash

newcleo (NASDAQ:NWCL) was trading down 6.9% on November 19, 2026, implying a prior close near USD 3.77 (calculated), already below the USD 4.01 close on November 17. On November 18, 2026 the company issued a third-quarter Business update and filed a prospectus supplement covering as many as 217,834,936 ordinary shares plus 9,146,717 shares tied to warrants, while 281.5 million shares were outstanding on September 30, 2026. The filing states no offering price, and the excerpt reviewed did not label it, though such a filing lets holders sell registered shares. The company announced no new financing. Cash was 233.4 million euros, up from 90.4 million euros a year earlier, and product and service revenue grew about 26%, to 9.95 million euros. The developer of lead-cooled reactors reached Nasdaq on September 22, 2026 through a merger with a blank-check company. Risks include a large block of registered shares reaching the market, small revenue against Capital spending, schedule slippage on its Italian demonstrator and licensing. No company announcement explaining the slide was found, and low-priced shares can see wide spreads.

Where Things Stand

A USD 150 million raise weighed most visibly on SELLAS Life Sciences (NASDAQ:SLS), down 13.98%, but the pattern is uneven across the four. ClearOne (NASDAQ:CLRO) fell 11.59% after a USD 4.00 share sale that added about 27% to its share count. newcleo (NASDAQ:NWCL) slid 6.9% beside a resale prospectus that registers no new cash. PepGen (NASDAQ:PEPG) rose 8.82% even though it remains below its USD 5.00 offering price. Only two of the four have a clear, company-announced share sale tied to the day, and none of the causes is confirmed by the companies. Next markers are the pricing of the SELLAS offering, the Nasdaq panel ruling for ClearOne, the closing of the PepGen deal and any holder selling by newcleo. None of this is a guarantee of future moves.